Status:

TERMINATED

Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients

Lead Sponsor:

British Columbia Cancer Agency

Conditions:

Constipation

Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and ...

Detailed Description

One group will be started on a bowel protocol of escalating doses of sennosides, plus a dummy polyethylene glycol (lactose), and the other will receive dummy sennosides capsules (lactose) plus polyeth...

Eligibility Criteria

Inclusion

  • Adult patient (18 years and above) with diagnosis of cancer.
  • Patient requires treatment or prevention of constipation.
  • Patient is able to communicate effectively with staff.
  • Expected prognosis more than 12 weeks.
  • On or starting opioid therapy

Exclusion

  • Patient unable to take oral medication.
  • Allergy or previous intolerance to PEG or sennosides.
  • Lactose intolerant.
  • Contraindication to PEG or sennosides.
  • Known or suspected bowel obstruction or ileus.
  • Colostomy or ileostomy.
  • Inflammatory bowel disease.
  • Hospitalisation expected within the study period.
  • Patient unable to complete the study diary in English.

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2018

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT01189409

Start Date

June 1 2010

End Date

October 1 2018

Last Update

August 28 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

BC Cancer Agency

Vancouver, British Columbia, Canada, V5Z 4E6

Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients | DecenTrialz